Vera Therapeutics (VERA) Non-Current Debt (2021 - 2026)

Vera Therapeutics (VERA) has 6 years of Non-Current Debt data on file, last reported at $75.0 million in Q1 2026.

• Quarterly Non-Current Debt rose 50.06% year-over-year to $75.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $75.0 million (up 50.06% YoY) and the FY2025 annual result came in at $74.8 million, up 49.68% from the prior year.
• Non-Current Debt was little changed at $75.0 million in Q1 2026, from $74.8 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $75.0 million in Q1 2026 to a low of $5.0 million in Q3 2022.
• A 5-year average of $42.0 million and a median of $50.0 million in 2024 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2023 — Non-Current Debt surged 403.42% — and 2025, when it decreased 0.13%.
• Tracing VERA's Non-Current Debt over 5 years: stood at $25.0 million in 2022, then soared by 99.51% to $49.9 million in 2023, then grew by 0.25% to $50.0 million in 2024, then surged by 49.68% to $74.8 million in 2025, then climbed by 0.26% to $75.0 million in 2026.
• The last three Non-Current Debt figures came in at $75.0 million (Q1 2026), $74.8 million (Q4 2025), and $75.0 million (Q3 2025), per Business Quant data.